1
|
Datta NR, Rogers S, Klingbiel D, Gómez S, Puric E, Bodis S. Hyperthermia and radiotherapy with or without chemotherapy in locally advanced cervical cancer: a systematic review with conventional and network meta-analyses. Int J Hyperthermia 2016; 32:809-21. [PMID: 27411568 DOI: 10.1080/02656736.2016.1195924] [Citation(s) in RCA: 62] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
PURPOSE A systematic review with conventional and network meta-analyses (NMA) was conducted to examine the outcomes of loco-regional hyperthermia (HT) with radiotherapy (RT) and/or chemotherapy (CT) in locally advanced cervix cancer, IIB-IVA (LACC). METHODS AND MATERIALS A total of 217 abstracts were screened from five databases and reported as per PRISMA guidelines. Only randomised trials with HT and RT ± CT were considered. The outcomes evaluated were complete response (CR), long-term loco-regional control (LRC), patients alive, acute and late grade III/IV toxicities. RESULTS Eight articles were finally retained. Six randomised trials with HTRT (n = 215) vs. RT (n = 212) were subjected to meta-analysis. The risk difference for achieving CR and LRC was greater by 22% (p < .001) and 23% (p < .001), respectively, with HTRT compared to RT. A non-significant survival advantage of 8.4% with HTRT was noted with no differences in acute or late toxicities. The only HTCTRT vs. RT trial documented a CR of 83.3% vs. 46.7% (risk difference: 36.7%, p = .001). No other end points were reported. Bayesian NMA, incorporating 13 studies (n = 1000 patients) for CR and 12 studies for patients alive (n = 807 patients), comparing HTCTRT, HTRT, CTRT and RT alone, was conducted. The pairwise comparison of various groups showed that HTRTCT was the best option for both CR and patient survival. This was also evident on ranking treatment modalities based on the "surface under cumulative ranking" values. CONCLUSIONS In LACC, HTRT demonstrates a therapeutic advantage over RT without significant acute or late morbidities. On NMA, HTCTRT appears promising, but needs further confirmation through prospective randomised trials.
Collapse
Affiliation(s)
- Niloy R Datta
- a Centre for Radiation Oncology , KSA-KSB, Kantonsspital Aarau , Aarau , Switzerland
| | - Susanne Rogers
- a Centre for Radiation Oncology , KSA-KSB, Kantonsspital Aarau , Aarau , Switzerland
| | - Dirk Klingbiel
- b Swiss Group for Clinical Cancer Research (SAKK) , Coordinating Centre , Bern , Switzerland
| | - Silvia Gómez
- a Centre for Radiation Oncology , KSA-KSB, Kantonsspital Aarau , Aarau , Switzerland
| | - Emsad Puric
- a Centre for Radiation Oncology , KSA-KSB, Kantonsspital Aarau , Aarau , Switzerland
| | - Stephan Bodis
- a Centre for Radiation Oncology , KSA-KSB, Kantonsspital Aarau , Aarau , Switzerland ;,c Department of Radiation Oncology , University Hospital Zurich , Zurich , Switzerland
| |
Collapse
|
2
|
Errachdi A, Asabbane A, Nkoua Epala B, Hemmich M, Kabbali N, Kebdani T, Benjaafar N. [Advanced cervical cancer: Evolutionary and prognostic. Moroccan experience]. Presse Med 2014; 43:e257-64. [PMID: 25001047 DOI: 10.1016/j.lpm.2014.02.029] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/01/2013] [Revised: 09/26/2013] [Accepted: 02/13/2014] [Indexed: 11/25/2022] Open
Abstract
INTRODUCTION Standard treatment of locally advanced cervical carcinoma is actually represented by concomitant chemoradiotherapy followed by brachytherapy. However, in spite of good local control rates after treatment, local and regional relapses still a major cause of failure treatment. The occurrence of progressions and relapses depends on prognostic factors of disease evolution. Their treatment is often palliative. METHODS The aim of this study is to report the evolution of our retrospective series after radiotherapy with or without concomitant chemotherapy, and to discuss progressions and relapses factors for the stages IIIB and IVA of cervical carcinoma. RESULTS Progressions occurred in 15 patients (13.7%) with an average of three months. Recurrences occurred in 15 patients (13.7%) with an average of 19.6 months. The overall treatment failure rate was 27.5%. Seventy-six of treated patients were in good locoregional control with a median follow of 64 months (61-76). The overall survival at five years was 41.3%. CONCLUSION Relapses of cervical cancer have a poor prognosis and long-term survival remains very poor. The suitable treatment of the primary disease, respecting essentially therapeutic times, is the only guarantee of a good prognosis, as well as screening at early stages, involving less poor prognostic factors.
Collapse
Affiliation(s)
- Amal Errachdi
- CHU Ibn Sina, Université Mohamed 5, Institut national d'oncologie Sidi-Mohamed-Benabdellah, service de radiothérapie, 10100 Rabat, Maroc.
| | - Amal Asabbane
- CHU Ibn Sina, Université Mohamed 5, Institut national d'oncologie Sidi-Mohamed-Benabdellah, service de radiothérapie, 10100 Rabat, Maroc
| | - Brice Nkoua Epala
- CHU Ibn Sina, Université Mohamed 5, Institut national d'oncologie Sidi-Mohamed-Benabdellah, service de radiothérapie, 10100 Rabat, Maroc
| | - Mariem Hemmich
- CHU Ibn Sina, Université Mohamed 5, Institut national d'oncologie Sidi-Mohamed-Benabdellah, service de radiothérapie, 10100 Rabat, Maroc
| | - Naoual Kabbali
- CHU Ibn Sina, Université Mohamed 5, Institut national d'oncologie Sidi-Mohamed-Benabdellah, service de radiothérapie, 10100 Rabat, Maroc
| | - Tayeb Kebdani
- CHU Ibn Sina, Université Mohamed 5, Institut national d'oncologie Sidi-Mohamed-Benabdellah, service de radiothérapie, 10100 Rabat, Maroc
| | - Noureddine Benjaafar
- CHU Ibn Sina, Université Mohamed 5, Institut national d'oncologie Sidi-Mohamed-Benabdellah, service de radiothérapie, 10100 Rabat, Maroc
| |
Collapse
|
3
|
Capelle L, Stevens W, Brooks S. Management pathway for patients with cervical cancer in the Auckland region 2003-2007. J Med Imaging Radiat Oncol 2011; 55:337-43. [PMID: 21696570 DOI: 10.1111/j.1754-9485.2011.02276.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
INTRODUCTION This review was performed to describe the patient pathway and timelines involved in the treatment of FIGO (International Federation of Gynecology and Obstetrics) stage IB1 to IVA cervical cancer in a New Zealand cancer centre. METHODS Retrospective audit of women with a new diagnosis of FIGO Stage IB1-IVA cervical cancer in the Auckland/Northland regions between 2003 and 2007. RESULTS Two hundred and seven patients were identified. Median time from referral to first specialist assessment (FSA) was 10days, from FSA to decision to treat (DTT) 50days and from DTT to start of treatment 26days. Overall median time from referral to start of treatment was 97days. There was no difference in median time from referral to DTT for patients treated with primary surgery (48days) or radiotherapy (47days). On univariate analysis, factors associated with reduced time from referral to start of treatment were less socioeconomic deprivation (P=0.001), shorter time to completion of radiological investigations (P<0.0005) and private FSA (P<0.0005). Only private FSA remained significant on multivariate analysis. The greatest delay in the pathway was between FSA and DTT, encompassing presentation at multidisciplinary meeting, examination under anaesthetic and obtaining radiological investigations. Median overall treatment time (OTT) for patients treated with definitive radiotherapy was 56days and was increased by a median of 3days where there were delays accessing operating theatre time for brachytherapy insertions. CONCLUSION Overall patient pathway and radiotherapy OTT were longer than optimal, and areas of delay potentially amenable to modification were identified.
Collapse
Affiliation(s)
- Lisa Capelle
- Department of Radiation Oncology, Auckland City Hospital Faculty of Medical Sciences, University of Auckland, Auckland, New Zealand.
| | | | | |
Collapse
|
4
|
Datta NR, Agrawal S. Does the evidence support the use of concurrent chemoradiotherapy as a standard in the management of locally advanced cancer of the cervix, especially in developing countries? Clin Oncol (R Coll Radiol) 2006; 18:306-12. [PMID: 16703748 DOI: 10.1016/j.clon.2005.12.005] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Locally advanced cancer of the cervix (FIGO stages III and IVA) is one of the most common malignancies in developing countries. Conventional treatment has been a judicious combination of external radiotherapy and intracavitary brachytherapy. However, prompted by the results of five randomised-controlled trials (RCTs) published in close succession, The National Cancer Institute (NCI) alert in 1999, and two meta-analyses, the management of cancer of the cervix has gradually changed. Concurrent chemoradiotherapy with cisplatin alone, or in combination, is gradually being favoured for the treatment of cancer of the cervix. This overview examines whether the published evidence is sufficiently adequate to justify the use of chemoradiotherapy using cisplatin as standard care in the management of cancer of the cervix, especially in developing countries, where most women present with locally advanced cancer of the cervix. A critical review of the various phase III randomised trials and meta-analyses indicates that, although chemoradiotherapy could be a standard form of treatment for early cancer of the cervix, its role in advanced stages needs further exploration before this could be incorporated into routine clinical care.
Collapse
Affiliation(s)
- N R Datta
- Department of Radiotherapy, Regional Cancer Centre, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
| | | |
Collapse
|
5
|
Datta NR, Kumar P, Singh S, Gupta D, Srivastava A, Dhole TN. Does pretreatment human papillomavirus (HPV) titers predict radiation response and survival outcomes in cancer cervix?—A pilot study. Gynecol Oncol 2006; 103:100-5. [PMID: 16563473 DOI: 10.1016/j.ygyno.2006.01.058] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2005] [Revised: 01/20/2006] [Accepted: 01/27/2006] [Indexed: 10/24/2022]
Abstract
OBJECTIVE To evaluate if pretreatment HPV titers in cancer cervix could predict radiation response and survival outcomes. METHODS Twenty-one patients of cancer cervix were treated by radiotherapy (RT) alone. HPV titers were estimated using DNA Hybrid Capture II test. Loco-regional response at 1 month of RT--complete or partial response (CR and PR respectively) and survival outcomes--local disease-free (LDFS), disease-free (DFS) and overall (OS) survivals were evaluated against pre- and posttreatment HPV titers. RESULTS Pretreatment HPV titers ranged from 0.81 to 3966.10 RLU/cut off (mean +/- SD: 1264.39 +/- 1148.22, median: 1129.98). Of the demographic features evaluated, mean HPV titers were significantly different only for patients achieving CR or PR at completion of RT (mean +/- SD for CR vs. PR: 1616.31 +/- 1146.86 vs. 384.57 +/- 538.80, P = 0.022). HPV titers at end of RT ranged from 0.12 to 487.42 RLU/cut off (mean +/- SD: 37.31 +/- 108.60, median: 2.33). Patients with higher pretreatment HPV titers (>1000 RLU/cutoff) had a higher CR (P = 0.022) and better survival compared to those with < or =1000 RLU/cutoff (LDFS, P = 0.004; DFS, P = 0.005; OS, P = 0.012). At completion of RT, those having > or =99.5% fall in HPV had superior survival outcomes than those with <99.5% reduction (LDFS, P = 0.002; DFS, P = 0.002; OS, P = 0.004). CONCLUSIONS Higher pretreatment HPV titers (>1000 RLU/cutoff) could be considered as a predictor of radiotherapy response and survival in cancer cervix. A reduction in these titers to 99.5% of their baseline values at end of radiotherapy is also associated with better survival outcomes.
Collapse
Affiliation(s)
- Niloy R Datta
- Department of Radiotherapy, Regional Cancer Centre, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Rae Barelli Road, Lucknow-226014, India.
| | | | | | | | | | | |
Collapse
|
6
|
Saibishkumar EP, Patel FD, Sharma SC, Karunanidhi G, Ghoshal S, Kumar V, Kapoor R. Prognostic value of response to external radiation in stage IIIB cancer cervix in predicting clinical outcomes: A retrospective analysis of 556 patients from India. Radiother Oncol 2006; 79:142-6. [PMID: 16677730 DOI: 10.1016/j.radonc.2006.03.016] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2005] [Revised: 11/10/2005] [Accepted: 03/23/2006] [Indexed: 11/26/2022]
Abstract
BACKGROUND AND PURPOSE To evaluate the prognostic significance of response to external beam radiation (EBRT) in predicting the clinical outcomes in stage IIIB cancer cervix and to find out factors affecting response to EBRT. PATIENTS AND METHODS This retrospective study included 556 patients of cancer cervix stage IIIB treated between 1996 and 2001 with EBRT (46Gy/23fx/4.5 weeks) followed by intracavitary radiotherapy (ICRT). At the end of EBRT, response to EBRT was grouped as 'no gross residual tumor'(NRT) or 'gross residual tumor'(GRT). RESULTS Follow up ranged from 2 to 93 months with a median of 36 months. Median dose to point A was 81Gy. At the end of EBRT, 393 patients (70.7%) attained NRT response. NRT responders had significantly better 5 year pelvic control, disease free survival (DFS) and overall survival (OS) than those who had a GRT response (75.6 vs. 54.6%; 60.6 vs. 31.9% and 62.6 vs. 33.7%, respectively; all P values <0.0001). Apart from response to EBRT, overall treatment time also has emerged as an independent factor to affect all clinical outcomes in multivariate analysis but age had significant impact on pelvic control only. Age was the only factor, which significantly influenced the response to EBRT in univariate as well as multivariate analysis (P=<0.001, OR=1.973, 95% C.I. 1.357-2.868). Patients with age more than 50 years had more NRT response (77%) than patients with age less than 50 years (63.8%). CONCLUSIONS Patients who attain NRT response to EBRT will have an impressive long term pelvic control, DFS and OS in stage IIIB cancer cervix. Older patients (>or=50 years) attain significantly higher NRT rates than younger patients.
Collapse
Affiliation(s)
- Elantholi P Saibishkumar
- Department of Radiotherapy, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
| | | | | | | | | | | | | |
Collapse
|
7
|
Singh S, Datta NR, Krishnani N, Lal P, Kumar S. Radiation therapy induced micronuclei in cervical cancer—does it have a predictive value for local disease control? Gynecol Oncol 2005; 97:764-71. [PMID: 15943985 DOI: 10.1016/j.ygyno.2005.02.016] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2004] [Revised: 02/09/2005] [Accepted: 02/10/2005] [Indexed: 11/30/2022]
Abstract
OBJECTIVE To evaluate the predictive value of serial changes in micronuclei induction during external radiotherapy (EXRT) in cervical cancer with respect to local response at the end of EXRT and local disease free survival (LDFS). METHODS Twenty-five patients of squamous cell cancer of the cervix were treated by 50 Gy of EXRT delivered over 5 weeks followed by intracavitary brachytherapy. Serial cytological smears were taken from cervical growth at weekly intervals during the course of EXRT and stained by Giemsa and May-Grunwald's stain. Micronuclei induction were scored as (a) number of cells expressing micronuclei (MN), and (b) total number of micronuclei (TMN) in 1000 tumor cells from each of the serial smears. RESULTS A significant rise in micronuclei count was seen for both MN and TMN from pretreatment (week 0) to successive weeks of EXRT. For those having a near total tumor regression by end of EXRT, a significant rise in micronuclei was evident even at the end of first week of EXRT (MN: P = 0.05, TMN: P = 0.04). A superior LDFS was observed in patients showing greater than 50% increment in MN value in the first week (median survival for <50% vs. > or =50% rise: 5 months vs. not reached, P = 0.21), while it reached significance for a similar rise of TMN (median survival <50% vs. > or =50% rise: 5 months vs. not reached, P = 0.04). CONCLUSIONS The significant rise of micronuclei at the end of first week of EXRT in cervical cancers as observed from serial cytological smears could predict for a better local response and LDFS.
Collapse
Affiliation(s)
- Shalini Singh
- Department of Radiotherapy, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Rae Barelli Road, Lucknow-226014, UP, India
| | | | | | | | | |
Collapse
|